Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Proinflammatory T helper type 17 cells are effective B-cell helpers.

Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14292-7. doi: 10.1073/pnas.1009234107. Epub 2010 Jul 26.

2.

Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation.

Lukacs NW, Smit JJ, Mukherjee S, Morris SB, Nunez G, Lindell DM.

J Immunol. 2010 Aug 15;185(4):2231-9. doi: 10.4049/jimmunol.1000733. Epub 2010 Jul 12.

3.

Tc17 cells are capable of mediating immunity to vaccinia virus by acquisition of a cytotoxic phenotype.

Yeh N, Glosson NL, Wang N, Guindon L, McKinley C, Hamada H, Li Q, Dutton RW, Shrikant P, Zhou B, Brutkiewicz RR, Blum JS, Kaplan MH.

J Immunol. 2010 Aug 15;185(4):2089-98. doi: 10.4049/jimmunol.1000818. Epub 2010 Jul 12.

4.

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.

Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J.

Vaccine. 2010 Aug 2;28(34):5543-50. doi: 10.1016/j.vaccine.2010.06.041. Epub 2010 Jun 25.

PMID:
20600502
5.

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H.

Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. Review.

6.

Defensins in viral infections.

Ding J, Chou YY, Chang TL.

J Innate Immun. 2009;1(5):413-20. doi: 10.1159/000226256. Epub 2009 Jun 24. Review.

7.

IL-10 deficiency unleashes an influenza-specific Th17 response and enhances survival against high-dose challenge.

McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, Tighe M, Hamada H, Sell S, Dutton RW, Swain SL.

J Immunol. 2009 Jun 15;182(12):7353-63. doi: 10.4049/jimmunol.0900657.

8.

Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice.

Kovacs-Nolan J, Mapletoft JW, Lawman Z, Babiuk LA, van Drunen Littel-van den Hurk S.

J Gen Virol. 2009 Aug;90(Pt 8):1892-905. doi: 10.1099/vir.0.011684-0. Epub 2009 Apr 22.

PMID:
19386785
9.

A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production.

Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, Kolls JK, Peebles RS Jr.

J Immunol. 2009 May 1;182(9):5317-21. doi: 10.4049/jimmunol.0803868.

10.

Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels.

Jaffar Z, Ferrini ME, Herritt LA, Roberts K.

J Immunol. 2009 Apr 15;182(8):4507-11. doi: 10.4049/jimmunol.0900237.

11.

Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge.

Hamada H, Garcia-Hernandez Mde L, Reome JB, Misra SK, Strutt TM, McKinstry KK, Cooper AM, Swain SL, Dutton RW.

J Immunol. 2009 Mar 15;182(6):3469-81. doi: 10.4049/jimmunol.0801814.

12.

A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction.

Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE Jr, Goleniewska K, Williams JV, Collins PL, Peebles RS Jr.

J Virol. 2009 May;83(9):4185-94. doi: 10.1128/JVI.01853-08. Epub 2009 Feb 11.

13.

IL-17 and Th17 Cells.

Korn T, Bettelli E, Oukka M, Kuchroo VK.

Annu Rev Immunol. 2009;27:485-517. doi: 10.1146/annurev.immunol.021908.132710. Review.

PMID:
19132915
14.

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.

Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP.

Nat Med. 2009 Jan;15(1):34-41. doi: 10.1038/nm.1894. Epub 2008 Dec 14.

15.
16.

In vitro activities of a novel nanoemulsion against Burkholderia and other multidrug-resistant cystic fibrosis-associated bacterial species.

LiPuma JJ, Rathinavelu S, Foster BK, Keoleian JC, Makidon PE, Kalikin LM, Baker JR Jr.

Antimicrob Agents Chemother. 2009 Jan;53(1):249-55. doi: 10.1128/AAC.00691-08. Epub 2008 Oct 27.

17.

Interferon-alpha controls IL-17 expression in vitro and in vivo.

Moschen AR, Geiger S, Krehan I, Kaser A, Tilg H.

Immunobiology. 2008;213(9-10):779-87. doi: 10.1016/j.imbio.2008.07.022. Epub 2008 Aug 30.

PMID:
18926293
18.

B cell antigen presentation promotes Th2 responses and immunopathology during chronic allergic lung disease.

Lindell DM, Berlin AA, Schaller MA, Lukacs NW.

PLoS One. 2008 Sep 3;3(9):e3129. doi: 10.1371/journal.pone.0003129.

19.

Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine.

Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, Wilkinson JE, Blanco LP, Landers JJ, Baker JR Jr.

PLoS One. 2008 Aug 13;3(8):e2954. doi: 10.1371/journal.pone.0002954.

20.

Supplemental Content

Support Center